Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: Results from the REPOSI registry

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1495-1503

  Pasina, L ^a   Brucato, A L ^b   Djade, C D ^a   Di Corato, P ^b   Ghidoni, S ^b   Tettamanti, M ^a   Franchi, C ^a   Salerno, F ^c   Corrao, S ^d   Marengoni, A ^e   Marcucci, M ^f   Mannucci, P M ^g   Nobili, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Aged; Allopurinol; Pharmacoepidemiology

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; XANTHINE OXIDASE;

AGED; ARTICLE; CHEMOTHERAPY INDUCED HYPERURICEMIA; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; GERIATRIC HOSPITAL; GERIATRIC PATIENT; GOUT; HEART ARRHYTHMIA; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERURICEMIA; INAPPROPRIATE PRESCRIBING; ISCHEMIC CARDIOMYOPATHY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; OBESITY; REGISTER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ANTAGONISTS AND INHIBITORS; HOSPITAL; ITALY; RISK; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOPURINOL; CROSS-SECTIONAL STUDIES; FEMALE; GOUT SUPPRESSANTS; HOSPITALS; HUMANS; HYPERURICEMIA; INAPPROPRIATE PRESCRIBING; ITALY; MALE; PATIENT ADMISSION; PATIENT DISCHARGE; REGISTRIES; RISK; THIAZOLES; XANTHINE OXIDASE;

EID: 84919922013     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1752-4     Document Type: Article

References (21)

1. Struthers A, Shearer F (2012) Allopurinol: novel indications in cardiovascular disease. Heart 98(21):1543-1545
2. Higgins P, Dawson J, Lees KR et al (2012) Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 30(4):217-226
3. Luk AJ, Levin GP, Moore EE et al (2009) Allopurinol and mortality in hyperuricaemic patients. Rheumatology 48(7):804-806
4. Thanassoulis G, Brophy JM, Richard H et al (2010) Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 9;170(15):1358-1364
5. Rentoukas E, Tsarouhas K, Tsitsimpikou C et al (2010) The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 145:257e8
6. Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388e93
7. Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P et al (2005) Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 17;331(7517): 623-624
8. Khanna D, Fitzgerald JD, Khanna PP et al (2012) American College of Rheumatology. American College of Rheumatology Guidelines for Management of Gout: part 1, systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431-1446
9. White WB, Chohan S, Dabholkar A et al (2012) Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J 164(1):14-20
10. Horsburgh S, Norris P, Becket G et al (2014) Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int 34(7):963-970
11. Gois PH, Souza ER (2013) Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev 1:CD008652
12. Palmer TM, Nordestgaard BG, Benn M et al (2013) Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 18;347: f4262
13. Kim SC, Newcomb C, Margolis D et al (2013) Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res 65(4):578-584
14. Singer JZ, Wallace SL (1986) The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 29(1): 82-87
15. Carnovale, C, Venegoni M, Clementi E. Allopurinol Overuse in Asymptomatic Hyperuricemia A Teachable Moment. JAMA Intern Med 2014. doi:10.1001/jamainternmed.2014.1427
16. Kang Y, Kim MJ, Jang HN et al (2014) Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. J Clin Pharm Ther 39(3):328-330
17. Becker MA (1988) Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin N Am 14:377
18. Dincer HE, Dincer AP, Levinson DJ (2002) Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 69(8):594-608, 597, 600-602
19. Kjellstrand CM, Cambell DC II, von Hartitzsch B et al (1974) Hyperuricemic acute renal failure. Arch Intern Med 133(3):349-359
20. Ettinger B, Tang A, Citron JT et al (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315(22):1386-1389
21. Mikuls TR, Farrar JT, Bilker WB et al (2005) Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 44(8):1038-1042